View Financial HealthEuroapi 배당 및 자사주 매입배당 기준 점검 0/6Euroapi 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris France공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.Board Change • Jan 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mattias Perjos was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Jan 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to €2.18. The fair value is estimated to be €2.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 4.1% in 2 years. Earnings are forecast to grow by 79% in the next 2 years.공시 • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.공시 • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026공시 • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.공시 • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.Board Change • Dec 30High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Chairman of the Board Viviane Monges is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Buy Or Sell Opportunity • Oct 29Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.4% to €3.52. The fair value is estimated to be €2.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.공시 • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.Buy Or Sell Opportunity • Oct 04Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to €3.62. The fair value is estimated to be €2.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.공시 • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025Reported Earnings • Aug 02First half 2024 earnings released: €0.37 loss per share (vs €0.67 profit in 1H 2023)First half 2024 results: €0.37 loss per share (down from €0.67 profit in 1H 2023). Revenue: €450.9m (down 9.5% from 1H 2023). Net loss: €34.8m (down 155% from profit in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany.공시 • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025New Risk • Jul 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €190m Forecast net loss in 3 years: €14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€161m). Currently unprofitable and not forecast to become profitable over next 3 years (€14m net loss in 3 years). Share price has been volatile over the past 3 months (9.1% average weekly change).공시 • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.공시 • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.Reported Earnings • Mar 01Full year 2023 earnings released: €2.01 loss per share (vs €0.16 loss in FY 2022)Full year 2023 results: €2.01 loss per share (further deteriorated from €0.16 loss in FY 2022). Revenue: €1.02b (up 3.9% from FY 2022). Net loss: €189.7m (loss widened €174.7m from FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorates as stock falls 42%After last week's 42% share price decline to €3.89, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 75% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €6.71 per share.Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €6.51. The fair value is estimated to be €5.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.Buy Or Sell Opportunity • Feb 16Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 25% to €6.56. The fair value is estimated to be €5.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.Buy Or Sell Opportunity • Jan 23Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 29% to €6.16. The fair value is estimated to be €5.08, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.공시 • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.공시 • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.공시 • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.Buying Opportunity • Oct 11Now 50% undervalued after recent price dropOver the last 90 days, the stock is down 49%. The fair value is estimated to be €10.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.공시 • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany.공시 • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024Reported Earnings • Mar 09Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.공시 • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.공시 • Dec 19Euroapi S.A.(ENXTPA:EAPI) dropped from FTSE All-World Index (USD)Euroapi S.A.(ENXTPA:EAPI) dropped from FTSE All-World Index (USD)공시 • Dec 07Euroapi S.A. Updates Revenue Guidance for the Year of 2022Euroapi S.A. updated revenue guidance for the year of 2022. For the year, the company updated net sales reaching circa €980 million.공시 • Sep 01+ 1 more updateEuroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023공시 • Jul 02Euroapi S.A. to Report First Half, 2022 Results on Sep 01, 2022Euroapi S.A. announced that they will report first half, 2022 results on Sep 01, 2022지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 940 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 940 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Euroapi 배당 수익률 vs 시장940의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (940)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (940) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 940 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 940 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 940 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 940 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 12:21종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Euroapi S.A.는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchFalko FriedrichsDeutsche Bank8명의 분석가 더 보기
공시 • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris France
공시 • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
Board Change • Jan 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mattias Perjos was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Jan 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to €2.18. The fair value is estimated to be €2.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 4.1% in 2 years. Earnings are forecast to grow by 79% in the next 2 years.
공시 • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.
공시 • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026
공시 • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.
공시 • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France
공시 • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
Board Change • Dec 30High number of new and inexperienced directorsThere are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Chairman of the Board Viviane Monges is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Buy Or Sell Opportunity • Oct 29Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.4% to €3.52. The fair value is estimated to be €2.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.
공시 • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.
Buy Or Sell Opportunity • Oct 04Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to €3.62. The fair value is estimated to be €2.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.
공시 • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025
Reported Earnings • Aug 02First half 2024 earnings released: €0.37 loss per share (vs €0.67 profit in 1H 2023)First half 2024 results: €0.37 loss per share (down from €0.67 profit in 1H 2023). Revenue: €450.9m (down 9.5% from 1H 2023). Net loss: €34.8m (down 155% from profit in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025
New Risk • Jul 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €190m Forecast net loss in 3 years: €14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€161m). Currently unprofitable and not forecast to become profitable over next 3 years (€14m net loss in 3 years). Share price has been volatile over the past 3 months (9.1% average weekly change).
공시 • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.
공시 • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.
Reported Earnings • Mar 01Full year 2023 earnings released: €2.01 loss per share (vs €0.16 loss in FY 2022)Full year 2023 results: €2.01 loss per share (further deteriorated from €0.16 loss in FY 2022). Revenue: €1.02b (up 3.9% from FY 2022). Net loss: €189.7m (loss widened €174.7m from FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorates as stock falls 42%After last week's 42% share price decline to €3.89, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 75% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €6.71 per share.
Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €6.51. The fair value is estimated to be €5.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.
Buy Or Sell Opportunity • Feb 16Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 25% to €6.56. The fair value is estimated to be €5.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.
Buy Or Sell Opportunity • Jan 23Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 29% to €6.16. The fair value is estimated to be €5.08, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
공시 • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.
공시 • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.
공시 • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.
Buying Opportunity • Oct 11Now 50% undervalued after recent price dropOver the last 90 days, the stock is down 49%. The fair value is estimated to be €10.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.
공시 • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.
공시 • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.
Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024
Reported Earnings • Mar 09Full year 2022 earnings releasedFull year 2022 results: Revenue: €980.9m (up 9.9% from FY 2021). Net loss: €15.0m (loss narrowed 5.1% from FY 2021). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Jan 12EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board of DirectorsThe board of directors of EUROAPI announced Corinne Le Goff, after serving as an independent member on the board of directors since May 6, 2022, has resigned from her directorship as of January 11, 2023.
공시 • Dec 19Euroapi S.A.(ENXTPA:EAPI) dropped from FTSE All-World Index (USD)Euroapi S.A.(ENXTPA:EAPI) dropped from FTSE All-World Index (USD)
공시 • Dec 07Euroapi S.A. Updates Revenue Guidance for the Year of 2022Euroapi S.A. updated revenue guidance for the year of 2022. For the year, the company updated net sales reaching circa €980 million.
공시 • Sep 01+ 1 more updateEuroapi S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023Euroapi S.A. announced that they will report fiscal year 2022 results Pre-Market on Mar 08, 2023
공시 • Jul 02Euroapi S.A. to Report First Half, 2022 Results on Sep 01, 2022Euroapi S.A. announced that they will report first half, 2022 results on Sep 01, 2022